<?xml version="1.0" encoding="UTF-8"?>
<xml>
<records>
<record>
	<source-app name="Actavia">Actavia</source-app>
	<ref-type name="Journal Article">0</ref-type>
	<contributors>
		<authors>
			<author>Dabrowska, Anna Maria</author>
			<author>Tarach, Jerzy Stanislaw</author>
			<author>Wojtysiak-Duma, Beata</author>
			<author>Duma, Dariusz</author>
		</authors>
		<secondary-authors></secondary-authors>
	</contributors>
	<titles><title>Fetuin-A (AHSG) and its usefulness in clinical practice. Review of the literature</title></titles>
	<dates>
		<year>2015</year>
		<pub-dates><date>2015-9-30</date></pub-dates>
	</dates>
	<pages>352-359</pages>
	<abstract>Background: Fetuin-A, also called Alpha 2-Heremans Schmid Glycoprotein, is a multifunctional plasma agent what has been proven in animal and human studies. It plays a role as a physiological inhibitor of insulin receptor tyrosine kinase associated with insulin resistance and a negative acute phase reactant. It also regulates bone remodeling and calcium metabolism being an important inhibitor of calcium salt precipitation and vascular calcifications.
Methods: PubMed database was searched for articles from 2002 up to December 2014 to identify the role of fetuin-A in the pathogenesis of selected internal diseases.
Results: Due to secretion of fetuin-A mainly by the liver, it may be a marker of liver function and predictor of mortality in patients with cirrhosis and hepatocellular cancer. The associations between high fetuin-A and metabolic syndrome as well as its hepatic manifestation- nonalcoholic fatty liver disease and atherogenic lipid profile have been well proven. However, fetuin-A relation with BMI is not so clear. Contrary to few reports, many authors suggest that fetuin-A may be an independent risk factor for type 2 diabetes and marker of diabetic complications. Close associations of high and low fetuin-A concentrations with cardiovascular diseases and mortality risk have been reported which is explained by differences in analyzed populations, stages of atherosclerosis and calcifications, coexistence of type 2 diabetes or kidney dysfunction and different main pathways of fetuin-A actions in various diseases.
Conclusions: Fetuin-A has a diagnostic potential as a biomarker for liver dysfunction, cardiovascular diseases and disorders associated with metabolic syndrome.</abstract>
	<number>3</number>
	<volume>159</volume>
</record>
</records>
</xml>
